Cargando…
Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review
Unlike chyloperitoneum associated with clinical conditions including cancer, cirrhosis, and traumatic surgery, calcium channel blocker (CCB)-associated chyloperitoneum is rarely discussed in comprehensive studies on chyloperitoneum. We aimed to investigate the prevalence and characteristics of CCB-a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517940/ https://www.ncbi.nlm.nih.gov/pubmed/31013922 http://dx.doi.org/10.3390/ijerph16081333 |
_version_ | 1783418357772451840 |
---|---|
author | Kim, Seungyeon Yu, Yun Mi Kwon, Jeongyoon Yoo, Hyejin Jung, Sun Hoi Lee, Euni |
author_facet | Kim, Seungyeon Yu, Yun Mi Kwon, Jeongyoon Yoo, Hyejin Jung, Sun Hoi Lee, Euni |
author_sort | Kim, Seungyeon |
collection | PubMed |
description | Unlike chyloperitoneum associated with clinical conditions including cancer, cirrhosis, and traumatic surgery, calcium channel blocker (CCB)-associated chyloperitoneum is rarely discussed in comprehensive studies on chyloperitoneum. We aimed to investigate the prevalence and characteristics of CCB-associated chyloperitoneum in peritoneal dialysis (PD) patients. The MEDLINE, Embase, CENTRAL, CiNii, and RISS databases were systematically searched for clinical studies on CCB-associated chyloperitoneum in PD patients published up to 31 July 2018. A total of 17 studies (four cohort studies, one case series, and 12 case reports) were selected. Eight CCBs, namely amlodipine, benidipine, diltiazem, lercanidipine, manidipine, nifedipine, nisoldipine, and verapamil, were reported to be associated with chyloperitoneum; manidipine and lercanidipine were the most frequently reported. The average prevalence of chyloperitoneum for lercanidipine was 25.97% in three cohort studies, two of which had a moderate or high risk of bias. Most of the studies revealed chyloperitoneum development within 4 days of initiation of CCB therapy and chyloperitoneum disappearance within 24 h of CCB withdrawal. The results of this study emphasise on the need for awareness among healthcare professionals regarding CCB-associated chyloperitoneum in PD patients. Further studies elucidating the causality and clinical implication of CCB-associated chyloperitoneum are needed. |
format | Online Article Text |
id | pubmed-6517940 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65179402019-05-31 Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review Kim, Seungyeon Yu, Yun Mi Kwon, Jeongyoon Yoo, Hyejin Jung, Sun Hoi Lee, Euni Int J Environ Res Public Health Review Unlike chyloperitoneum associated with clinical conditions including cancer, cirrhosis, and traumatic surgery, calcium channel blocker (CCB)-associated chyloperitoneum is rarely discussed in comprehensive studies on chyloperitoneum. We aimed to investigate the prevalence and characteristics of CCB-associated chyloperitoneum in peritoneal dialysis (PD) patients. The MEDLINE, Embase, CENTRAL, CiNii, and RISS databases were systematically searched for clinical studies on CCB-associated chyloperitoneum in PD patients published up to 31 July 2018. A total of 17 studies (four cohort studies, one case series, and 12 case reports) were selected. Eight CCBs, namely amlodipine, benidipine, diltiazem, lercanidipine, manidipine, nifedipine, nisoldipine, and verapamil, were reported to be associated with chyloperitoneum; manidipine and lercanidipine were the most frequently reported. The average prevalence of chyloperitoneum for lercanidipine was 25.97% in three cohort studies, two of which had a moderate or high risk of bias. Most of the studies revealed chyloperitoneum development within 4 days of initiation of CCB therapy and chyloperitoneum disappearance within 24 h of CCB withdrawal. The results of this study emphasise on the need for awareness among healthcare professionals regarding CCB-associated chyloperitoneum in PD patients. Further studies elucidating the causality and clinical implication of CCB-associated chyloperitoneum are needed. MDPI 2019-04-13 2019-04 /pmc/articles/PMC6517940/ /pubmed/31013922 http://dx.doi.org/10.3390/ijerph16081333 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kim, Seungyeon Yu, Yun Mi Kwon, Jeongyoon Yoo, Hyejin Jung, Sun Hoi Lee, Euni Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review |
title | Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review |
title_full | Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review |
title_fullStr | Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review |
title_full_unstemmed | Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review |
title_short | Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review |
title_sort | calcium channel blocker-associated chyloperitoneum in patients receiving peritoneal dialysis: a systematic review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517940/ https://www.ncbi.nlm.nih.gov/pubmed/31013922 http://dx.doi.org/10.3390/ijerph16081333 |
work_keys_str_mv | AT kimseungyeon calciumchannelblockerassociatedchyloperitoneuminpatientsreceivingperitonealdialysisasystematicreview AT yuyunmi calciumchannelblockerassociatedchyloperitoneuminpatientsreceivingperitonealdialysisasystematicreview AT kwonjeongyoon calciumchannelblockerassociatedchyloperitoneuminpatientsreceivingperitonealdialysisasystematicreview AT yoohyejin calciumchannelblockerassociatedchyloperitoneuminpatientsreceivingperitonealdialysisasystematicreview AT jungsunhoi calciumchannelblockerassociatedchyloperitoneuminpatientsreceivingperitonealdialysisasystematicreview AT leeeuni calciumchannelblockerassociatedchyloperitoneuminpatientsreceivingperitonealdialysisasystematicreview |